- Home
- IFRX vs AKA Comparison
IFRX vs AKA Comparison
Compare IFRX & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- AKA
- Stock Information
- Founded
- IFRX 2007
- AKA 2018
- Country
- IFRX Germany
- AKA United States
- Employees
- IFRX N/A
- AKA N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- AKA Catalog/Specialty Distribution
- Sector
- IFRX Health Care
- AKA Consumer Discretionary
- Exchange
- IFRX Nasdaq
- AKA Nasdaq
- Market Cap
- IFRX 117.8M
- AKA 126.7M
- IPO Year
- IFRX 2017
- AKA 2021
- Fundamental
- Price
- IFRX $1.00
- AKA $13.50
- Analyst Decision
- IFRX Strong Buy
- AKA Buy
- Analyst Count
- IFRX 2
- AKA 4
- Target Price
- IFRX $9.00
- AKA $24.50
- AVG Volume (30 Days)
- IFRX 322.6K
- AKA 6.6K
- Earning Date
- IFRX 05-07-2025
- AKA 05-07-2025
- Dividend Yield
- IFRX N/A
- AKA N/A
- EPS Growth
- IFRX N/A
- AKA N/A
- EPS
- IFRX N/A
- AKA N/A
- Revenue
- IFRX $171,642.00
- AKA $574,697,000.00
- Revenue This Year
- IFRX $106.72
- AKA $6.56
- Revenue Next Year
- IFRX $66.89
- AKA $4.25
- P/E Ratio
- IFRX N/A
- AKA N/A
- Revenue Growth
- IFRX 162.79
- AKA 5.21
- 52 Week Low
- IFRX $1.01
- AKA $8.89
- 52 Week High
- IFRX $2.82
- AKA $33.73
- Technical
- Relative Strength Index (RSI)
- IFRX 33.87
- AKA 50.30
- Support Level
- IFRX $1.01
- AKA $13.83
- Resistance Level
- IFRX $1.18
- AKA $15.75
- Average True Range (ATR)
- IFRX 0.12
- AKA 0.91
- MACD
- IFRX 0.01
- AKA 0.24
- Stochastic Oscillator
- IFRX 3.66
- AKA 48.89
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.